Hokkaido University · 의학
Hajime Asahina 교수의 연구실은 비소세포성 폐암의 표적치료 및 면역치료에 초점을 맞추고 있으며, 특히 EGFR 돌연변이를 가진 환자에게서의 페지티닙 등의 표적치료제 효과와 고령 환자에서의 면역관문 억제제 치료 전략을 중심으로 연구를 진행하고 있습니다. 또한, 실시간 EBUS 유도 생검 기술의 정밀도 향상과 신약 후보물질인 린리판브의 임상적 유효성에 대한 연구도 병행하고 있습니다. 이는 환자 중심의 정밀의료 실현을 목표로 한 종양내과 기반의 임상 연구입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Gefitinib represents a useful therapeutic option for selected previous gefitinib responders.
In this study, ICI-chemotherapy combination treatment did not improve survival and increased the incidence of grade 3 and higher immune-related adverse events compared with ICI alone in patients 75 years and older. Based on these results, ICI alone may be recommended for older adult patients with PD-L1-positive NSCLC.
ICI is also effective in elderly NSCLC patients, and treatment discontinuation due to irAEs may be a good prognostic marker.
Linifanib was well tolerated with promising preliminary clinical activity in Japanese patients. Later-phase global studies examining linifanib efficacy will include Japanese patients.
Our attempt to perform TBB under real-time EBUS guidance for PPLs was successful in 4 of 6 patients. There were some technical limitations using flexible bronchoscopy with 2 working channels. Improvement of instruments will be necessary for future trials of TBB under real-time EBUS guidance.
13014 Background: Activating mutations in exon 18–21 of the epidermal growth factor receptor (EGFR) gene have been reported to be a predictor of response to gefitinib. We conducted a phase II study to evaluate the efficacy and safety of gefitinib as a first-line therapy for advanced non-small cell lung cancers (NSCLCs) with EGFR gene mutations. Methods: The primary endpoint was response rate (RR). Eligiblity criteria were stage IIIB or IV chemotherapy naive NSCLC, ECOG PS of 0–2, adequate organ
